Comparison between One Injection and Three Monthly Injections of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization
- 25 October 2011
- journal article
- research article
- Published by S. Karger AG in Ophthalmic Research
- Vol. 47 (3) , 135-140
Abstract
Aim: To compare the effects of one intravitreal bevacizumab (IVB) injection with three monthly injections for myopic choroidal neovascularization. Methods: Group A included 13 patients treated with one IVB injection; group B included 19 patients treated with three monthly 1.25-mg IVB injections. All patients were followed monthly for 12 months with additional injections performed as needed. The best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evaluated before and after treatment. Results: The mean logMAR BCVA improved from 0.59 to 0.49 at 12 months in group A (p = 0.21) and from 0.65 to 0.29 in group B (p < 0.001); the improved logMAR BCVA differed significantly between the groups (p < 0.05). The mean CFT decreased from 231 µm at baseline to 150 µm at 12 months in group A (p < 0.05) and from 279 to 156 µm in group B (p < 0.001). During the follow-up, 6 of 13 eyes in group A and 5 of 19 eyes in group B received additional injections. Conclusions: Treatment starting with three monthly IVB injections may achieve better functional outcomes with fewer retreatments compared with treatment starting with one IVB injection.Keywords
This publication has 18 references indexed in Scilit:
- Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2010
- Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2009
- INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIARetina, 2009
- Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month resultsEye, 2009
- Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcomeBritish Journal of Ophthalmology, 2008
- A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2008
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007
- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopiaOphthalmology, 2003
- Surgical removal of subfoveal choroidal neovascularisation in highly myopic patientsBritish Journal of Ophthalmology, 2001